Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Teva
McKesson
Johnson and Johnson
Express Scripts
Baxter
Merck
Dow
Federal Trade Commission

Generated: July 20, 2018

DrugPatentWatch Database Preview

Pentazocine hydrochloride - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for pentazocine hydrochloride and what is the scope of pentazocine hydrochloride freedom to operate?

Pentazocine hydrochloride
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for pentazocine hydrochloride.
Summary for pentazocine hydrochloride
Synonyms for pentazocine hydrochloride
(+-)-Pentazocine hydrochloride
(2alpha,6alpha,11R*)-(1)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol hydrochloride
(2alpha,6alpha,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol hydrochloride
(2R*,6R*,11R*)-1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol hydrochloride
(2s,6s)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol hydrochloride(1:1)
1,2,3,4,5,6-hexahydro-6,11-dimethyl-3- -2,6-methano-3-benzazocin-8-olhydrochloride
1,2,3,4,5,6-Hexahydro-6,11-dimethyl-3-(3-methylbut-2-enyl)-2,6-methano-3-benzazocin-8-ol hydrochloride
2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, hydrochloride
2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, hydrochloride, (2-alpha,6-alpha,11R*)-(+-)-
2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, hydrochloride, (2alpha,6alpha,11R*)-
2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-, hydrochloride, (2R,6R,11R)-rel-
2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-,hydrochloride, (2-alpha,6-alpha,11R*)-(+-)-
22205-05-6
2276-52-0
23559-80-0
359-83-1 (Parent)
41690-02-2
41819-21-0
64024-15-3
68964-90-9
AC1L32RO
AC1L53YT
AC1Q3F7P
C19H27NO.HCl
CHEMBL1200349
D02227
EINECS 218-896-9
EINECS 264-612-1
EINECS 273-423-3
LS-90599
OQGYMIIFOSJQSF-UHFFFAOYSA-N
Pentazocine HCl
Pentazocine hydrochloride (JAN/USP)
Pentazocine hydrochloride [USAN:USP]
Pentazocine hydrochloride [USAN]
Pentazocinhydrochlorid
SCHEMBL40963
SCHEMBL40964
Sosegon (TN)
Talacen (TN)
Talwin (as hydrochloride)
Talwin 50
UNII-A36BXO4PPX component OQGYMIIFOSJQSF-DTOXXUQYSA-N
UNII-A36BXO4PPX component OQGYMIIFOSJQSF-NMVCJIEOSA-N

US Patents and Regulatory Information for pentazocine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us TALWIN 50 pentazocine hydrochloride TABLET;ORAL 016732-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Daiichi Sankyo
US Department of Justice
Julphar
Queensland Health
Deloitte
Cantor Fitzgerald
Fuji
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.